Connection
Search Results to J. Steven Leeder
This is a "connection" page, showing the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of
Leeder, J. Steven
Property | Value |
keywords
|
Pediatric Clinical Pharmacology
|
keywords
|
Clinical Pharmacology
|
research overview
|
In his former role as Director of the Division of Clinical Pharmacology and Therapeutic Innovation at Children’s Mercy Dr. Leeder led a program consisting of multidisciplinary teams of researchers with expertise in analytical chemistry, drug biotransformation, gene regulation, pharmacogenomics, and pharmacokinetics to investigate variability in medication response in children. An important component of the program was to provide an environment in which trainees and early career faculty members from diverse backgrounds could develop as independent investigators in their areas of research interest. These research interests generally are closely aligned with their clinical expertise with the goal of implementing precision therapeutics in their clinical subspecialties to benefit the patients they serve.
Currently, Dr Leeder is Executive Director (Interim) of the Children’s Mercy Research Institute and leads the Precision Therapeutics Area of Emphasis. The Precision Therapeutics initiative extends the Division of Clinical Pharmacology's emphasis on developing individuals to a more institutional level by providing support to pediatric subspecialties interested in adding precision therapeutics to their portfolio of research programs. In this way the program serves as a model of integrated research that will extend throughout the CMRI.
Over the years, Dr. Leeder's research interests in pediatric pharmacogenetics and the ontogeny of drug biotransformation pathways during growth and development have coalesced into the GOLDILOKs initiative: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids. Originally funded as one of four Specialized Centers for Research in Pediatric Developmental Pharmacology supported by the Eunice Kennedy Shriver National Institute for Child Health and Human Development, "GOLDILOKs" now represents a conceptual approach to better understanding factors contributing to variability in drug disposition and response and using that information to make the use of medications safer and more effective in children of all ages.
Dr. Leeder is also co-PI, with Dr. Mario Castro (KUMC), of the Frontiers Clinical and Translational Science Institute at the University of Kansas.
|
One or more keywords matched the following items that are connected to
Leeder, J. Steven
Item Type | Name |
Academic Article
|
Developmental pharmacology--drug disposition, action, and therapy in infants and children.
|
Academic Article
|
Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology.
|
Academic Article
|
In: Handbook of Experimental Pharmacology Volume 121: Drug-Induced Hepatotoxicity. Cameron RG, Feuer G and de la Iglesia F, Eds
|
Academic Article
|
In: Neonatal and Pediatric Pharmacology, Third Edition, Yaffe S and Aranda J, (Eds)
|
Academic Article
|
In: Neonatal and Pediatric Pharmacology, Fourth Edition, Yaffe S and Aranda J, (Eds
|
Academic Article
|
In: Textbook of Pediatric Rheumatology, Seventh Edition, Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, (Eds)
|
Grant
|
Ontogeny and Genetics of NSAID Dose-Exposure Relationship in Preterm Infants
|
Award or Honor Receipt
|
Rawls-Palmer Progress in Medicine Award
|
Award or Honor Receipt
|
Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics
|
Grant
|
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
|
Grant
|
Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology
|
Grant
|
Effect of Obesity on Pantoprazole Pharmacokinetics and Pharmacodynamics in Children
|
Award or Honor Receipt
|
Clarivate Highly Cited Researcher – 2021, Pharmacology and Toxicology
|
|
|